JP2023509442A5 - - Google Patents

Info

Publication number
JP2023509442A5
JP2023509442A5 JP2022540916A JP2022540916A JP2023509442A5 JP 2023509442 A5 JP2023509442 A5 JP 2023509442A5 JP 2022540916 A JP2022540916 A JP 2022540916A JP 2022540916 A JP2022540916 A JP 2022540916A JP 2023509442 A5 JP2023509442 A5 JP 2023509442A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
amino
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067576 external-priority patent/WO2021138498A1/en
Publication of JP2023509442A publication Critical patent/JP2023509442A/ja
Publication of JP2023509442A5 publication Critical patent/JP2023509442A5/ja
Pending legal-status Critical Current

Links

JP2022540916A 2020-01-03 2020-12-30 Cd73阻害剤とa2a/a2bアデノシン受容体阻害剤の併用療法 Pending JP2023509442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956840P 2020-01-03 2020-01-03
US62/956,840 2020-01-03
PCT/US2020/067576 WO2021138498A1 (en) 2020-01-03 2020-12-30 Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2023509442A JP2023509442A (ja) 2023-03-08
JP2023509442A5 true JP2023509442A5 (cg-RX-API-DMAC10.html) 2024-01-10

Family

ID=74236306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540916A Pending JP2023509442A (ja) 2020-01-03 2020-12-30 Cd73阻害剤とa2a/a2bアデノシン受容体阻害剤の併用療法

Country Status (13)

Country Link
US (2) US12060433B2 (cg-RX-API-DMAC10.html)
EP (1) EP4084870A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023509442A (cg-RX-API-DMAC10.html)
KR (1) KR20220137013A (cg-RX-API-DMAC10.html)
CN (1) CN115551595A (cg-RX-API-DMAC10.html)
AU (1) AU2020419293A1 (cg-RX-API-DMAC10.html)
CA (1) CA3166536A1 (cg-RX-API-DMAC10.html)
CL (2) CL2022001795A1 (cg-RX-API-DMAC10.html)
IL (1) IL294437A (cg-RX-API-DMAC10.html)
MX (1) MX2022007573A (cg-RX-API-DMAC10.html)
PH (1) PH12022551621A1 (cg-RX-API-DMAC10.html)
TW (1) TW202135823A (cg-RX-API-DMAC10.html)
WO (1) WO2021138498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) * 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
WO2021247188A1 (en) * 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001080884A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
EP1883424A2 (en) 2005-05-18 2008-02-06 Biogen Idec Inc. Methods for treating fibrotic conditions
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
EP3259288B1 (en) 2015-02-20 2026-07-22 Innate Pharma Cd73 blockade
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
EP3481869A4 (en) * 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
CA3046432A1 (en) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anti-human cd73 antibody
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CN119431579A (zh) 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
AU2019231172B2 (en) 2018-03-09 2023-08-24 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
EP3810610A1 (en) * 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019232244A2 (en) * 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
MX2021005248A (es) 2018-11-05 2021-08-11 Corvus Pharmaceuticals Inc Anticuerpos contra cd73 activadores de células b.
KR20210093255A (ko) 2018-11-12 2021-07-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技(成都)有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
JP7623706B2 (ja) 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Cd73に特異的な結合分子と結合分子の使用
CN117946274B (zh) 2019-06-19 2026-02-17 杭州博之锐生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN115141277A (zh) 2019-08-21 2022-10-04 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
PH12022550470A1 (en) 2019-08-26 2023-02-27 Incyte Corp Triazolopyrimidines as a2a / a2b inhibitors
EP4025605A1 (en) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
CA3159196A1 (en) 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
EP4058150A2 (en) 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
EP4076669A4 (en) 2019-12-19 2024-01-10 Board of Regents, The University of Texas System METHOD FOR TREATING GLIOBLASTOMA
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
WO2021213466A1 (zh) 2020-04-22 2021-10-28 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN115551888B (zh) 2020-05-12 2026-04-28 百欧恩泰(珠海)医药研发有限公司 抗cd73抗体及其用途
CN115867582A (zh) 2020-05-29 2023-03-28 朝途生物疗法株式会社 抗cd73抗体及其用途
CN115734972A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法

Similar Documents

Publication Publication Date Title
JP2024502005A5 (cg-RX-API-DMAC10.html)
JP2023509456A5 (cg-RX-API-DMAC10.html)
US11780845B2 (en) FGFR inhibitors and methods of use thereof
JP7723666B2 (ja) 環式化合物およびその使用方法
JP2013523884A5 (cg-RX-API-DMAC10.html)
JP7860103B2 (ja) 複素環式スピロ化合物及びその使用方法
TWI820209B (zh) 三唑并-嘧啶化合物及其用途
JP6336598B2 (ja) 抗増殖性化合物
JP2016514718A5 (cg-RX-API-DMAC10.html)
KR101696525B1 (ko) Btk 활성 억제제로서의 8-플루오로프탈라진-1(2h)-온 화합물
KR102359759B1 (ko) 세린/트레오닌 키나제 저해제
CN108430993A (zh) Tank-结合激酶抑制剂化合物
TW202108572A (zh) Cdk抑制劑
JP2010510319A5 (cg-RX-API-DMAC10.html)
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
JP2024536858A5 (cg-RX-API-DMAC10.html)
MX2015004615A (es) Inhibidores de serina/treonina cinasa.
JP2020526549A5 (cg-RX-API-DMAC10.html)
JP2013518823A5 (cg-RX-API-DMAC10.html)
JP2025524002A (ja) 環式化合物及びそれを使用する方法
JP2022535108A5 (cg-RX-API-DMAC10.html)
JP2024532780A5 (cg-RX-API-DMAC10.html)
JP2020531487A5 (cg-RX-API-DMAC10.html)
US20260138956A1 (en) Novel compounds and uses thereof
RU2021118348A (ru) Циклические тетрамерные соединения как ингибиторы пропротеин-конвертазы субтилизин/кексин типа 9 (pcsk9) для лечения метаболических нарушений